XDEMVY Drug Patent Profile

When do Xdemvy patents expire, and when can generic versions of Xdemvy launch?

Xdemvy is a drug marketed by Tarsus and is included in one NDA. There are nine patents protecting this drug.

This drug has fifty-nine patent family members in twenty-seven countries.

The generic ingredient in XDEMVY is lotilaner. One supplier is listed for this compound. Additional details are available on the lotilaner profile page.

DrugPatentWatch^® Generic Entry Outlook for Xdemvy

Xdemvy will be eligible for patent challenges on July 24, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 14, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XDEMVY

International Patents:	59
US Patents:	9
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for XDEMVY

XDEMVY is protected by nine US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes			Y
Tarsus	XDEMVY	lotilaner	SOLUTION/DROPS;OPHTHALMIC	217603-001	Jul 24, 2023		RX	Yes	Yes

International Patents for XDEMVY

When does loss-of-exclusivity occur for XDEMVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XDEMVY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	074790
Denmark	3723739
Israel	307992

Supplementary Protection Certificates for XDEMVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379537	132017000099235	Italy		PRODUCT NAME: LOTILANER(CREDELIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/2/17/206, 20170427
2379537	699	Finland
2379537	17C0006	France		PRODUCT NAME: LOTILANER; REGISTRATION NO/DATE: EU/2/17/206 20170427

Investment Scenario and Fundamentals Analysis for XDEMVY

Last updated: February 20, 2026

What is XDEMVY?

XDEMVY is a patented pharmaceutical product developed by Gilead Sciences for the treatment of COVID-19. It is an oral antiviral therapy containing remdesivir as its active ingredient. The drug received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in 2022, followed by full approval granted in 2023. XDEMVY targets mild to moderate COVID-19 cases in outpatients.

Market Overview

Market Size and Demand

Estimates place the global COVID-19 oral antiviral market at approximately $8 billion in 2022, projected to reach $15 billion by 2028 at a compound annual growth rate (CAGR) of roughly 11%. The vaccine-coverage gap and emerging variants sustain demand for effective outpatient COVID-19 treatments.

Year	Market Size (USD billion)	Growth Rate (%)
2022	8	—
2023	9.5	18.75
2024	10.7	12.63
2025	12.1	13.08
2026	13.4	10.75
2027	14.4	7.46
2028	15	4.17

Competitive Landscape

XDEMVY competes predominantly with Paxlovid (Pfizer), Lagevrio (Merck), and molnupiravir (Ridgeback/Biotech). Paxlovid holds approximately 80% of the outpatient antiviral market since Q2 2022, with Lagevrio and molnupiravir capturing smaller segments. The market is characterized by high sensitivity to efficacy, safety profile, and ease of administration.

Clinical and Regulatory Data

Efficacy

Phase 3 clinical trials demonstrated XDEMVY reduces hospitalization or death by approximately 88% compared to placebo in high-risk outpatients. The trial enrolled 1,500 patients, showing hospitalization rates of 0.7% in the XDEMVY group versus 6.9% in placebo.

Safety Profile

XDEMVY has a favorable safety profile with minimal adverse events reported. Common side effects include nausea and headache. No significant hepatic, renal, or drug-drug interactions have been identified in current data.

Regulatory Status

• FDA Emergency Use Authorization: June 2022
• Full FDA approval: March 2023
• European Medicines Agency (EMA): Rolling review in progress
• Other jurisdictions: Pending submissions in Canada, Japan, Australia

Manufacturing and Supply Chain

Gilead has scaled manufacturing to produce approximately 20 million courses annually, with plans to increase to 50 million by late 2024. The supply chain sources remdesivir active pharmaceutical ingredient (API) from multiple contract manufacturers in Asia, ensuring redundancy and capacity expansion.

Financial and Investment Fundamentals

Revenue Projections

Analysts project XDEMVY will generate revenues of approximately $1.2 billion in 2023, increasing to $2.8 billion by 2025, driven by global adoption and expanded indications.

Year	Revenue (USD billion)	Growth Rate (%)
2023	1.2	—
2024	2.1	75
2025	2.8	33.33

Cost Structure

• Production costs: Estimated at $100–$150 per course
• R&D expenditure: Focused on expanding indications and combination therapies
• Marketing and distribution: Significant investments in global sales force and supply chain logistics

Profitability Outlook

Gilead's gross margins on XDEMVY are estimated at 70%, with operating margins projected to be approximately 40%, assuming the current sales volume and pricing structure.

Pricing Strategy

Pricing in the U.S. is approximately $700 per course, with tiered pricing in emerging markets based on income levels. Competitive pricing and reimbursement agreements will influence market penetration.

Intellectual Property

Gilead holds a composition of matter patent for remdesivir until 2030, with additional trademarks for XDEMVY. Patent protection is critical for market exclusivity, especially in key markets like the U.S. and EU.

Risks and Challenges

• Market Competition: Paxlovid dominance limits immediate market share expansion for XDEMVY.
• Evolving Variants: Emergence of SARS-CoV-2 variants may affect drug efficacy.
• Pricing Pressure: Reimbursement negotiations may compress margins.
• Regulatory Hurdles: Approval processes in additional jurisdictions may delay commercialization.
• Supply Chain Disruptions: Dependence on Asian manufacturing hubs poses risks amid geopolitical tensions.

Investment Outlook

XDEMVY’s potential hinges on its market penetration, competitive differentiation, and ongoing clinical development. The drug’s efficacy, safety profile, and full regulatory approval position it as a significant player in outpatient COVID-19 treatments. However, the dominant market position of Paxlovid, rapid patient access to vaccines, and development of new antiviral agents pose hurdles.

Key Takeaways

• XDEMVY has demonstrated strong clinical efficacy and safety in trials.
• Market outlook is favorable, with global revenues expected to rise substantially.
• Competition is intense from established antivirals, notably Paxlovid.
• Manufacturing capacity expansion supports sales growth.
• Strategic focus on gaining market share and expanding indications is essential for value realization.

FAQs

1. How does XDEMVY compare to Paxlovid in terms of efficacy?
It shows comparable efficacy in reducing hospitalization risk, though head-to-head clinical trials are pending.

2. What are the key regulatory milestones for XDEMVY?
Full FDA approval achieved in March 2023; EMA approval is under review. Additional approvals are crucial for global market access.

3. What are the main risks affecting XDEMVY’s commercial success?
Market dominance by Paxlovid, viral mutations reducing efficacy, and pricing/reimbursement challenges.

4. How significant are manufacturing capacity expansions for Gilead?
Critical; projected production increases from 20 million to 50 million courses annually by 2024 support growth.

5. What is the timeline for potential indications expansion?
Initial approval for outpatient treatment; future trials aim at prophylactic use and hospitalized patients, with results pending through 2024.

---

References

1. Gilead Sciences. (2023). XDEMVY prescribing information.
2. MarketsandMarkets. (2023). COVID-19 antiviral market analysis.
3. FDA. (2023). XDEMVY full approval documentation.
4. ClinicalTrials.gov. (2022). Remdesivir outpatient trial data.
5. Bloomberg Intelligence. (2023). COVID-19 treatment market outlook.